

16th February, 2026

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AKAAR

Dear Sir/ Madam,

Sub.: Press Release

Please find enclosed herewith a copy of a Press Release titled '**XOMAGE® Plant Exosomes Registration (Korea)**' which will be disseminated shortly. The Press Release is self-explanatory.

The above information is also being made available on the website of the Company at <https://akaarmedical.in/disclosures-as-per-regulation-46-of-the-sebi-lodr-regulations/>

Thanking you,

Yours truly,
For Aakaar Medical Technologies Ltd.

Anoopkumar V. Pillai
Company Secretary & Compliance Officer

Encl: as above.

XOMAGE® Plant Exosomes Registration (Korea)

Aakaar Medical Technologies Ltd has entered into a strategic tie-up with TESS CO. LTD /Zishel Medical, South Korea, for the registration and future commercialization of XOMAGE Plant Exosomes. This initiative marks Aakaar's entry into the regenerative aesthetics and advanced skin biology segment.

Market Context and Rationale

The global medical aesthetics market is estimated at ~USD 28–30 billion (2024–25) and projected to reach ~USD 85–90 billion by 2034, reflecting a ~13–14% CAGR, driven by demand for advanced, evidence-based aesthetic solutions.

The exosome market for cosmetic and aesthetic applications was valued at approximately USD 1.8 billion (2024) and is projected to exceed USD 25 billion by 2035, growing at ~25–30% CAGR, making it one of the fastest-growing segments within regenerative aesthetics.

Exosome-based skincare and regenerative products are expected to grow from ~USD 0.8–0.9 billion (2024–25) to ~USD 3.5–4.0 billion by 2035, supported by increasing clinical adoption and post-procedure recovery use cases.

Plant-derived exosomes are gaining traction due to ethical sourcing, scalability, and regulatory friendliness compared with human- or animal-derived exosomes.

Strategic Impact for Aakaar

Adds a future-facing regenerative biologics line aligned with global trends toward biology-led aesthetics.

Enables protocol-based integration with existing dermatology devices, injectables, and cosmeceuticals, supporting higher clinic realization and cross-selling.

Positions Aakaar to participate in high-margin, high-growth regenerative categories such as skin rejuvenation, hair restoration, and post-procedure repair.

Strengthens Aakaar's long-term innovation pipeline and differentiation in the Indian and regional medical aesthetics market.

For Aakaar Medical Technologies Ltd.

Dr. Rahul B. Sawakhande
CEO & Director
Mumbai,
16.02.2026

